The Future of Clinical Trial Transparency

Presented by: Niamh McGuinness, Senior CTT Analyst, Privacy Analytics & Peter Mesenbrink, Executive Director of Biostatistics, Novartis Pharmaceuticals Corporation

Overview

In this session, we’ll discuss three emergent trends destined to have a major impact on your transparency planning for 2021. The race to create effective drug responses to COVID-19 has driven new levels of collaboration and is forcing clinical trial sponsors to think prospectively about the different contexts in which their trial data may be re-used to improve health outcomes. At the same time, clinical document sharing regulations continue to evolve. Your transparency teams need to meet these challenges head-on if your organization wants to remain viable.

Featured Topics

• The shift in clinical trial transparency regulations and expectations
• Robust data-sharing strategies to enhance brand reputation and foster internal innovation
• The role of statistical anonymization in producing useful data and documents for secondary use

Learning Objectives

Upon completion of the webinar, participants will have a better understanding of:

• Understand what the transition from competitive (data-sheltering) to collaborative (data-sharing) means for your organization
• Learn how a global drug developer ensured success with its safe & responsible COVID-19 data sharing
• Discover how statistical anonymization balances data utility and patient privacy